Cell-free biotech could drive COVID-19 therapeutics
Updated: Feb 7, 2021
Platform could produce new antiviral drugs more than 10 times faster
A biomanufacturing company spun out of the DLRG is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert F. Smith School of Chemical and Biomolecular Engineering, and his longtime collaborator, Michael Jewett, a professor of chemical and biological engineering at Northwestern University.
To learn more, see the stories:
https://news.cornell.edu/stories/2020/04/cell-free-biotech-could-drive-covid-19-therapeutics